Orexigen(R) Therapeutics Announces Third Quarter 2008 Financi...(tockholders' equity: Preferred st...)

Preferred stock, $.001 par value,

10,000,000 shares authorized at

September 30, 2008 and December 31, 2007;

no shares issued and outstanding at

September 30, 2008 and December 31, 2007 - -

Common stock, $.001 par value,

100,000,000 shares authorized at

September 30, 2008 and December 31, 2007;

34,423,322 and 26,982,601 shares

issued and outstanding at September 30,

2008 and December 31, 2007, respectively 34 27

Additional paid-in capital 251,375 171,571

Accumulated other comprehensive income 56 220

Deficit accumulated during the

development stage (178,049) (106,935)

Total stockholders' equity 73,416 64,883

Total liabilities and stockholders' equity $105,432 $91,320

Orexigen Therapeutics, Inc.

(a development stage company)

Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

Period from

September 12,

2002

(Inception)

Three Months Ended Nine Months Ended to

September September September

30, 30, 30,

2008 2007 2008 2007 2008

Revenues:

Collaborative agreem
'/>"/>